Michael Petusky, an analyst from Barrington, maintained the Buy rating on Henry Schein. The associated price target remains the same with $78.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Michael Petusky has given his Buy rating due to a combination of factors including the stability and growth potential in Henry Schein’s key markets. The company has seen a positive shift in its dental markets, particularly in Europe, with Germany showing signs of recovery after a challenging period. Despite uncertainties in U.S. trade policy, the overall macroeconomic environment appears favorable for Henry Schein.
Additionally, the company’s focus on high-growth, high-margin segments such as specialty dental and technology/value-add portfolios is expected to drive significant value. The ongoing recovery from a past cyber-incident and strategic efforts to convert episodic customers into loyal ones through promotional activities further strengthen its market position. Moreover, the collaboration with KKR’s Capstone value creation team to enhance margins and optimize operations underscores the company’s commitment to long-term growth and efficiency.
In another report released today, Piper Sandler also maintained a Buy rating on the stock with a $77.00 price target.